Back
1 min read
[Press Release] XAV19 : validation of the first dose of anti-Covid treatment of XENOTHERA
-
- Author Bertrand Fabien
- Published 12 novembre 2020
Related Posts
May, 2025. XENOTHERA, a French biotechnology company based in Nantes and a pioneer in the development of genetically modified pigs for therapeutic purposes, welcomes the publication of the National Academy of Medicine's report…
Read MoreDecember, 2024. XENOTHERA reaches important milestones in its oncology and onco-hematology clinical trials….
Read MoreNovember, 2024. The PALT24 project (Polyspecific Antibodies in Lymphoproliferative T cell disorders) targets a critical onco-hematological disease with a notably low prognosis.
Read More